Novo Nordisk Unveils DKK 15 Billion Buyback After 27% Sickle Cell Trial Success
Novo Nordisk launched a DKK 15 billion share repurchase program over 12 months starting February, representing up to 2% of its market cap. The company also reported its sickle cell therapy etavopivat reduced vaso-occlusive crises by 27% and delayed first events by four months, underlining its competitive edge.
1. DKK 15 Billion Share Repurchase Program
Novo Nordisk initiated a DKK 15 billion share repurchase on February 4, to be executed over a 12-month period under EU Safe Harbour rules. The program aims to offset dilution from employee plans and return capital to shareholders, equal to roughly 2% of its market capitalization.
2. Sickle Cell Therapy Etavopivat Data
The company's experimental oral etavopivat demonstrated a 27% reduction in vaso-occlusive crisis events and a four-month delay to first crisis on top of standard care. This clinical milestone highlights Novo Nordisk’s accelerating hemoglobinopathy portfolio and strengthens its lead over smaller rivals.
3. Competitive Impact and Pipeline Diversification
Positive etavopivat results drove Agios Pharmaceuticals shares down over 25%, underscoring the trial’s market impact. Meanwhile, Novo Nordisk is diversifying its obesity pipeline with cagrilintide, forecast to generate $771 million by 2031 in the emerging calcitonin receptor segment.